CPR Therapeutics joins inaugural Auxilium–MBI accelerator cohort

CPR Therapeutics, a Worcester-area medical device startup developing next-generation CPR technology, was selected for the first Auxilium–MBI Accelerator cohort in Massachusetts. The three-month program includes a $250,000 investment, mentorship and investor access as the company advances toward FDA submission.

Why it matters: - CPR Therapeutics is working on a CPR system aimed at improving survival after sudden cardiac arrest, which remains one of the leading causes of death worldwide. - Intact survival after sudden cardiac arrest remains below 10% in most communities, underscoring the need for better emergency tools. - The accelerator selection brings capital, mentorship and network access at a stage when the company is pushing toward FDA submission.

What happened: - CPR Therapeutics announced on July 15, 2026, that it was selected for the inaugural cohort of the Auxilium–MBI Accelerator in Worcester, Massachusetts. - The company is a preclinical medical device firm funded by the NIH and NSF. - The accelerator is a three-month, in-person program for early-stage life sciences and healthcare companies. - Auxilium and Massachusetts Biomedical Initiatives jointly operate the program. - The inaugural cohort includes four companies spanning medtech, diagnostics, artificial intelligence and healthcare innovation.

The details: - The accelerator provides a $250,000 investment to each selected company. - The program also offers mentorship, fundraising support and access to investor and industry networks from both organizations. - CPR Therapeutics is developing circumferential multimodal CPR, which the company says is more effective and less injurious than existing solutions. - The company describes its technology as an advanced-technology automated CPR system that combines multiple technologies into one system for emergency use. - CPR Therapeutics says the system could deliver clinically significant improvements in intact survival after sudden cardiac arrest. - The company notes that more than 300,000 deaths occur each year following sudden cardiac arrest in the U.S. alone. - Norman Paradis, CPR Therapeutics founder and CEO, said the program’s mentorship and access to the Worcester life sciences ecosystem come at an important time as the company advances toward FDA submission. - Paradis also said the Auxilium–MBI investment will unlock multiple matching commitments already in hand. - Emma Gatti, an engineer at CPR Therapeutics and a Worcester Polytechnic Institute graduate, said Worcester has become a world-class center for life sciences and that MBI’s experience with medical device companies makes the region an ideal setting for the startup. - Gatti said the company looks forward to working alongside the other cohort members. - More information about the accelerator is available at Auxilium Worcester.

Between the lines: - The selection gives CPR Therapeutics outside validation from two Worcester-area life sciences groups with local investor and industry reach. - The $250,000 investment appears to be as important as the program itself because it may trigger additional matching capital the company already has lined up. - Placement in a small inaugural cohort suggests the accelerator is positioning these companies as high-potential bets across multiple healthcare categories.

What's next: - CPR Therapeutics will participate in the three-month in-person accelerator in Worcester. - The company plans to keep advancing its technology toward FDA submission. - The startup will also work with the accelerator’s mentors, investors and industry contacts as it seeks additional financing and development milestones.